Close
An early clinical trial recently showed that the new Moderna COVID-19 booster could be an effective shield against the variants of coronavirus originally found in South Africa and Brazil.
According to ScienceAlert, the American biotech company began to develop variant-specific boosters earlier this year after evidence that several variants of COVID-19 can break through present vaccines.
This is Moderna s pioneering clinical trial in humans, following early trials on mice, and so far, the results are found promising.
Stephen Bancel, Moderna CEO said in a press release the company posted on its website, they are encouraged by this new date, which strengthens their confidence that their booster scheme should be protective against the said newly-identified variants.